Cytokinetics Inc. (CYTK) stock forecast and price target
Price $56.13 · data as of November 13, 2026
12-month price target
Average target$109.42
Upside / downside+94.9%
Analysts19
ConsensusStrong buy
Low $78.00Average $109.42High $146.00
Gold marker: average target · white marker: today’s price ($56.13)
Analyst ratings
Strong buy 7Buy 13Hold 2Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-5.76 | +11.9% | $165M |
| Next fiscal year ends December 31, 2027 | $-4.23 | +26.6% | $443M |
| Next quarter ends December 31, 2026 | $-1.35 | +9.9% | $65M |
| Quarter after ends March 31, 2027 | $-1.28 | +23.2% | $75M |
Consensus of the analysts covering Cytokinetics, updated daily. In the last 30 days 8 estimates were raised and 2 lowered.
Frequently asked questions
What is the Cytokinetics stock price target?
The average 12-month target from 19 analysts is $109.42, 94.9% above the current price of $56.13 Targets range from $78.00 to $146.00.
Is Cytokinetics a buy according to analysts?
The consensus rating is “Strong buy” (7 strong buy, 13 buy, 2 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Cytokinetics expected to earn?
Analysts expect EPS of $-5.76 for the fiscal year ending December 31, 2026 and $-4.23 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.